Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Hep B DNA levels predict hepatocellular cancer risk

This week's Journal of the American Medical Association shows that elevated serum Hepatitis B DNA level is a strong risk predictor of hepatocellular carcinoma, independent of Hep B e antigen, and liver cirrhosis.

News image

fiogf49gjkf04

Serum Hepatitis B DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic Hepatitis B.

Dr Chien-Jen Chen and colleagues from Taiwan evaluated the relationship between serum Hepatitis B DNA level and hepatocellular carcinoma risk.

The investigators conducted a cohort study of 3653 participants aged 30 to 65 years.

The patients were seropositive for the Hepatitis B surface antigen and seronegative for antibodies against the Hepatitis C virus.

The team recruited the patients at a community-based cancer screening program between 1991 and 1992.

The risk by serum Hep B DNA levels was significant after adjusting for cigarette smoking
Journal of the American Medical Association

The main outcome measure was the incidence of hepatocellular carcinoma during follow-up examination.

The incidence of hepatocellular carcinoma was also determined by data linkage with the national cancer registry and the death certification systems.

The team had 164 incident cases of hepatocellular carcinoma and 346 deaths during a mean follow-up of 11 years and 41,779 person-years of follow-up.

The incidence of hepatocellular carcinoma increased with serum Hepatitis B DNA level at study entry in a dose-response relationship.

The doses ranged from 108 per 100,000 person-years for a Hepatitis B DNA level of less than 300 copies/mL to 1152 per 100,000 person-years for a level of 1 million copies/mL or greater.

The investigators observed that the corresponding cumulative incidence rates of hepatocellular carcinoma for the above doses were 1% and 15%, respectively.

The biological gradient of hepatocellular carcinoma by serum Hepatitis B DNA levels remained significant after adjustment for sex, age, and cigarette smoking.

The biological gradient of hepatocellular carcinoma by serum Hepatitis B DNA was also significant after adjusting for alcohol consumption, and liver cirrhosis at study entry.

This remained significant when adjusting for serostatus for the Hepatitis B e antigen, and serum alanine aminotransferase levels.

The dose-response relationship was most prominent for participants who were seronegative for Hepatitis B e antigen.

These participants also had normal serum alanine aminotransferase levels and no liver cirrhosis at study entry.

Participants with persistent elevation of serum Hepatitis B DNA level during follow-up had the highest hepatocellular carcinoma risk.

Dr Chen's team commented, “Elevated serum Hepatitis B DNA level is a strong risk predictor of hepatocellular carcinoma independent of Hepatitis B e antigen, serum alanine aminotransferase level, and liver cirrhosis.”

JAMA 2006: 295(1): 65-73
06 January 2006

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us